Summary of Jasper Therapeutics Conference Call Company Overview - **Company**: Jasper Therapeutics (NasdaqCM: JSPR) - **Date of Conference**: November 12, 2025 Key Points Industry and Product Insights - **Product**: Bromelamab, a drug under investigation for conditions related to mast cell-mediated diseases, including Chronic Spontaneous Urticaria (CSU) and asthma [1][2] - **Clinical Trials**: Ongoing studies to evaluate the efficacy and safety of bromelamab in various cohorts, particularly focusing on patient responses and dosing strategies [4][20] Clinical Data and Findings - **Patient Response Rates**: In a recent study, only 2 out of 10 patients showed complete responses, contrasting with previous studies where response rates were around 60-70% [3][4] - **Investigation of Anomalous Results**: The company is investigating the patient selection process and study conduct at a specific site that enrolled five patients, which may have skewed results [5][6] - **Pharmacokinetics (PK) and Tryptase Levels**: Serum concentrations of bromelamab were consistent with previous studies, indicating that the drug was effectively administered [2] Future Actions and Studies - **Redosing Strategy**: All patients will receive at least three doses to identify any late responders and gather safety data on repeat dosing [6][26] - **Enhanced Patient Selection**: Stricter inclusion-exclusion criteria are being implemented to ensure accurate diagnosis of CSU by expert physicians [8][9] - **Asthma Study Update**: The asthma study was halted due to concerns over the drug lot used, but data from 12-15 patients will be available by the end of the year [10][11] Upcoming Data and Expectations - **Phase 2B Study Plans**: The company plans to initiate a Phase 2B study in mid-2026, based on the data collected from ongoing studies [20] - **Data Availability**: A significant amount of data, including redosing results and safety profiles, is expected to be available in early Q1 of the following year [22][26] Safety and Efficacy Considerations - **Safety Data Importance**: The safety of repeat dosing at 240 mg is a critical focus, as previous data indicated a high efficacy rate with this dosage [6][24] - **Long-term Follow-up**: The company will conduct long-term follow-up on patients to assess the safety and efficacy of the treatment [26] Conclusion - **Overall Sentiment**: The company remains optimistic about the potential of bromelamab, emphasizing the importance of understanding patient selection and drug efficacy in future studies [19][20]